New PET scan could help doctors choose the right chemo for cancer patients

NCT ID NCT05065736

Terminated Diagnosis Sponsor: Roberto Vargas Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This early-phase trial is testing whether a new radioactive tracer called 18F-Clofarabine (CFA) can be used in PET scans to measure an enzyme activity in cancer cells that may predict how well certain drugs like gemcitabine work. Four adults with metastatic cancer will receive the tracer and undergo PET/CT imaging. The study aims to see if the tracer's uptake in tumors correlates with standard imaging and disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-Clofarabine (a radioactive tracer for PET imaging)
What this could lead to: If successful, this could lead to a new imaging test that helps doctors predict which patients will respond to certain chemotherapy drugs like gemcitabine.
What could go wrong: This is a very early, small trial with only 4 participants. It is testing the imaging agent itself, not a treatment, so there is no direct benefit to participants. The tracer may not reliably predict drug response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma carcinoma metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOCARCINOMA CARCINOMA METASTATIC CANCER

Contacts and locations

Locations

Cleveland Clinic, Case Comprehensive Cancer Center

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.